<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fludarabine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fludarabine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fludarabine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8452" href="/d/html/8452.html" rel="external">see "Fludarabine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11348" href="/d/html/11348.html" rel="external">see "Fludarabine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708775"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fludarabine can severely suppress bone marrow function.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Autoimmune effects:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Instances of life-threatening and sometimes fatal autoimmune phenomena, such as hemolytic anemia, autoimmune thrombocytopenia/thrombocytopenic purpura, Evans syndrome, and acquired hemophilia, have been reported to occur after 1 or more cycles of treatment with fludarabine. Patients undergoing treatment with fludarabine should be evaluated and closely monitored for hemolysis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">When used at high doses in dose-ranging studies in patients with acute leukemia, fludarabine was associated with severe neurologic effects, including blindness, coma, and death. This severe CNS toxicity occurred in 36% of patients treated with dosages approximately 4 times greater (96 mg/m<sup>2</sup>/day for 5 to 7 days) than the recommended dosage. Similar severe CNS toxicity, including agitation, coma, confusion, and seizures, has been reported (0.2% or less) in patients treated at doses in the range of the dose recommended for chronic lymphocytic leukemia.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Combination with pentostatin:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In a clinical investigation using fludarabine in combination with pentostatin (deoxycoformycin) for the treatment of refractory chronic lymphocytic leukemia, there was an unacceptably high incidence of fatal pulmonary toxicity. Therefore, the use of fludarabine in combination with pentostatin is not recommended.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fludarabine injection should be administered under the supervision of a qualified health care provider experienced in the use of antineoplastic therapy.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866913"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Fludara</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1047440"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Antimetabolite</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Antimetabolite (Purine Analog)</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Antimetabolite (Purine Antagonist)</span></li></ul></div>
<div class="block dop drugH1Div" id="F171891"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">Refer to individual protocols; details concerning dosing in combination regimens should also be consulted.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fd9b583-2fce-41e1-8b73-a1be2090e860">Acute lymphocytic leukemia or AML, relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphocytic leukemia (ALL) or AML, relapsed:</b> Limited data available: Children and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: 10.5 mg/m<sup>2</sup> bolus followed by 30.5 mg/m<sup>2</sup>/<b>day</b> for 48 hours in combination with cytarabine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9516951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9516951'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV dosing: 25 mg/m<sup>2</sup> once daily for 5 days in combination with cytarabine and daunorubicin was used for ALL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21131038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21131038'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7b81f22-60bb-4e6c-beef-651807d9c3e8">Stem cell transplant conditioning regimen, reduced-intensity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stem cell transplant (allogeneic) conditioning regimen, reduced-intensity (hematologic malignancy):</b> Limited data available: Children and Adolescents: IV: 30 mg/m<sup>2</sup> once daily for 6 doses beginning 7 to 10 days prior to transplant (in combination with busulfan and thymoglobulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19528536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19528536'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="30fb95c3-a119-4722-8ca2-1393c4642817">Stem cell transplant conditioning regimen, reduced-toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stem cell transplant (allogeneic) conditioning regimen, reduced-toxicity (myeloid malignancies and non-malignant diseases [eg, sickle cell disease]):</b> Limited data available: Children and Adolescents: IV: 30 mg/m<sup>2</sup> once daily for 6 doses days -8 to -3 (in combination with busulfan and alemtuzumab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24797180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24797180'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic or nonhematologic toxicity (other than neurotoxicity): Consider treatment delay or dosage reduction.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemolysis: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Neurotoxicity: Consider treatment delay or discontinuation.</p></div>
<div class="block dorp drugH1Div" id="F51110619"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: The following guidelines have been used by some clinicians (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>): IV:</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 80% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: Administer 25% of dose</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous ambulatory peritoneal dialysis (CAPD): Not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): Administer 80% of dose.</p></div>
<div class="block doa drugH1Div" id="F171872"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8452" href="/d/html/8452.html" rel="external">see "Fludarabine: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Prophylactic anti-infectives should be considered for patients with an increased risk for developing opportunistic infections. Consider hydration and prophylactic antihyperuricemic therapy in patients at risk for tumor lysis syndrome.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad84c70c-a932-492d-bd7b-1b0f109f4056">Acute myeloid leukemia, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia, newly diagnosed (off-label use): IV:</b> 30 mg/m<sup>2</sup>/day for 5 days (in combination with cytarabine ± G-CSF ± idarubicin (FA, FLAG, or FLAG-IDA regimens), followed by consolidation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18932257','lexi-content-ref-23940227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18932257','lexi-content-ref-23940227'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>C</i>
<i>ore binding factor acute myeloid leukemia:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients ≤60 years of age: <b>IV:</b> 30 mg/m<sup>2</sup>/day for 5 days (in combination with filgrastim, cytarabine, and gemtuzumab ozogamicin), followed by postremission therapy of 30 mg/m<sup>2</sup>/day for 3 days (in combination with filgrastim, cytarabine, and gemtuzumab ozogamicin) for 6 postremission cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24990142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24990142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients &gt;60 years of age: <b>IV:</b> 30 mg/m<sup>2</sup>/day for 4 days (in combination with filgrastim, cytarabine, and gemtuzumab ozogamicin), followed by postremission therapy of 30 mg/m<sup>2</sup>/day for 3 days (in combination with filgrastim, cytarabine, and gemtuzumab ozogamicin) for 6 postremission cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24990142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24990142'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f20a47d6-66de-4ccb-ab05-6cdd77371373">Acute myeloid leukemia, refractory or high/poor-risk patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia, refractory or high/poor-risk patients (off-label use):</b>
<b>IV:</b> 30 mg/m<sup>2</sup>/day for 5 days (in combination with cytarabine and filgrastim [FLAG regimen]), may repeat once for partial remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9625576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9625576'])">Ref</a></span>) <b>or</b> 30 mg/m<sup>2</sup>/day for 5 days for 1 or 2 cycles (in combination with cytarabine, idarubicin, and filgrastim [FLAG-IDA regimen]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14675405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14675405'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20062019-4bc5-44ef-aea4-4125afe591df">Chronic lymphocytic leukemia, previously untreated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic lymphocytic leukemia, previously untreated (off-label dosing/combinations):</b></p>
<p style="text-indent:-2em;margin-left:6em;">FC regimen: <b>IV: </b>30 mg/m<sup>2</sup>/day for 3 days every 28 days for 6 cycles (in combination with cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16219797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16219797'])">Ref</a></span>) <b>or</b> 20 mg/m<sup>2</sup>/day for 5 days every 28 days for 6 cycles (in combination with cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17283364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17283364'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">FCR regimen: <b>IV: </b>25 mg/m<sup>2</sup>/day for 3 days every 28 days for 6 cycles (in combination with cyclophosphamide and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27216274','lexi-content-ref-26486789','lexi-content-ref-15767648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27216274','lexi-content-ref-26486789','lexi-content-ref-15767648'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">FR regimen: <b>IV: </b>25 mg/m<sup>2</sup>/day for 5 days every 28 days for 6 cycles (in combination with rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12393429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12393429'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="616b3161-d0d0-43a4-86a0-f2d33acde343">Chronic lymphocytic leukemia, refractory or progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia, refractory or progressive (off-label dosing/combination):</b></p>
<p style="text-indent:-2em;margin-left:4em;">FCR regimen: <b>IV: </b>25 mg/m<sup>2</sup>/day for 3 days every 28 days for 6 cycles (in combination with cyclophosphamide and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20194844','lexi-content-ref-15767647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20194844','lexi-content-ref-15767647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b> (Canadian product; not available in US): 40 mg/m<sup>2</sup> once daily for 5 consecutive days every 28 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5e92d74-e7b2-4fc9-93f6-490437e5896d">Chronic lymphocytic leukemia, Richters transformation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia, Richters transformation</b>
<b> (off-label dosing/combination): </b>OFAR regimen: <b>IV: </b>30 mg/m<sup>2</sup>/day for 2 days every 28 days for 6 cycles (in combination with oxaliplatin, cytarabine, and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18182662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18182662'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c48c48e5-c2f8-4d10-8750-83df9f1f0e9c">Hematopoietic cell transplant, allogeneic, myeloablative conditioning regimen</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic cell transplant, allogeneic, myeloablative conditioning regimen (off-label use): IV:</b> 40 mg/m<sup>2</sup>/day for 4 days (in combination with busulfan) beginning 6 days prior to transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26429297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26429297'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b108304-fd61-4782-858e-5546a2983551">Hematopoietic cell transplant, allogeneic, nonmyeloablative conditioning regimen</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic cell transplant, allogeneic, nonmyeloablative conditioning regimen (off-label use): IV:</b> 30 mg/m<sup>2</sup>/day for 3 doses beginning 5 days prior to transplant (in combination with cyclophosphamide and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18411419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18411419'])">Ref</a></span>) <b>or</b> 30 mg/m<sup>2</sup>/day for 3 doses beginning 4 or 7 days prior to transplant (in combination with total body irradiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25652604','lexi-content-ref-16344316','lexi-content-ref-12393457','lexi-content-ref-18056679','lexi-content-ref-31247313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25652604','lexi-content-ref-16344316','lexi-content-ref-12393457','lexi-content-ref-18056679','lexi-content-ref-31247313'])">Ref</a></span>). Refer to protocols for further details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="529e0a1f-f243-4024-818a-1d37d9b86027">Hematopoietic cell transplant, allogeneic, reduced-intensity conditioning regimen</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic cell transplant, allogeneic, reduced-intensity conditioning regimen (off-label use):</b>
<b>IV:</b> 30 mg/m<sup>2</sup>/day for 5 days (in combination with melphalan and alemtuzumab) prior to transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16314618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16314618'])">Ref</a></span>) <b>or</b> 30 mg/m<sup>2</sup>/day for 6 days beginning 10 days prior to transplant <b>or</b> 30 mg/m<sup>2</sup>/day for 5 days beginning 6 days prior to transplant (in combination with busulfan with or without antithymocyte globulin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14716342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14716342'])">Ref</a></span>) <b>or</b> 30 mg/m<sup>2</sup>/day for 2 days beginning 4 days prior to transplant (in combination with cyclophosphamide and thiotepa) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11756155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11756155'])">Ref</a></span>) <b>or</b> 25 mg/m<sup>2</sup>/day for 5 days (in combination with melphalan) prior to transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15806128']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15806128'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="220e7cd8-9c58-4b08-8248-a4212d14000c">Lymphodepleting therapy prior to chimeric antigen receptor T-cell immunotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphodepleting therapy prior to chimeric antigen receptor T-cell immunotherapy (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to axicabtagene ciloleucel: </i>
<b>IV: </b>30 mg/m<sup>2</sup>/day for 3 days (in combination with cyclophosphamide) beginning 5 days (on days −5, −4, and −3) prior to chimeric antigen receptor (CAR) T-cell infusion on day 0 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30518502','lexi-content-ref-34891224','lexi-content-ref-29226797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30518502','lexi-content-ref-34891224','lexi-content-ref-29226797'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to brexucabtagene autoleucel: </i>
<b>IV:</b> 30 mg/m<sup>2</sup>/day for 3 days (in combination with cyclophosphamide; for relapsed/refractory mantle cell lymphoma) beginning 5 days (on days −5, −4, and −3) prior to CAR T-cell infusion on day 0 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32242358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32242358'])">Ref</a></span>) <b>or</b> 25 mg/m<sup>2</sup>/day for 3 days beginning 4 days (on days −4, −3, and −2) prior to CAR T-cell infusion on day 0 (in combination with cyclophosphamide; for relapsed/refractory B-cell precursor acute lymphoblastic leukemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34097852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34097852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to ciltacabtagene autoleucel: </i>
<b>IV: </b>30 mg/m<sup>2</sup>/day for 3 days (in combination with cyclophosphamide) followed 2 to 4 days later by CAR T-cell infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34175021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34175021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to idecabtagene vicleucel: </i>
<b>IV: </b>30 mg/m<sup>2</sup>/day for 3 days (in combination with cyclophosphamide) beginning 5 days (on days −5, −4, and −3) prior to CAR T-cell infusion on day 0 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33626253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33626253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to lisocabtagene maraleucel: </i>
<b>IV: </b>30 mg/m<sup>2</sup>/day for 3 days (in combination with cyclophosphamide) followed 2 to 7 days later by CAR T-cell infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32888407']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32888407'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to tisagenlecleucel</i>
<i>:</i>
<b>IV: </b>25 mg/m<sup>2</sup>/day for 3 days (in combination with cyclophosphamide; for relapsed/refractory diffuse large B-cell lymphoma) followed 2 to 11 days later by CAR T-cell infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501490'])">Ref</a></span>) <b>or</b> 30 mg/m<sup>2</sup>/day for 4 days (in combination with cyclophosphamide; for relapsed/refractory B-cell acute lymphoblastic leukemia) followed 2 to 14 days later by CAR T-cell infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29385370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29385370'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d7759ad-c8d8-4d9d-8a77-fa0039ab2d14">T-cell large granular lymphocytic leukemia, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>T-cell large granular lymphocytic leukemia, relapsed/refractory (off-label use): IV: </b>25 mg/m<sup>2</sup>/day for 3 days every 28 days for 4 to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12588360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12588360'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c5acfef-6596-497f-90bd-63216cb2807e">T-cell prolymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>T-cell prolymphocytic leukemia (off-label use): </b>
<i>FMC-A regimen: </i>
<b>IV:</b> 25 mg/m<sup>2</sup> on days 1, 2, and 3 every 28 days (in combination with mitoxantrone and cyclophosphamide [FMC]) for 2 to 4 cycles; if response demonstrated after initial 2 FMC cycles, then an additional 2 cycles of FMC were administered, followed by alemtuzumab consolidation; if stable disease or progression observed after initial 2 FMC cycles, then proceeded directly to alemtuzumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23512246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23512246'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebda9a81-6b8d-4064-acf9-5c892f36549f">Waldenström macroglobulinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Waldenström macroglobulinemia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Fludarabine monotherapy: <b>IV:</b> 25 mg/m<sup>2</sup>/day for 5 days every 28 days for 2 cycles after achieving complete or maximum response, up to a maximum of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10080598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10080598'])">Ref</a></span>) <b>or</b> 30 mg/m<sup>2</sup>/day for 5 days every 28 days for at least 4 cycles; patients with a response received 4 additional cycles or 2 cycles beyond the maximum response level (whichever occurred earlier) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11418461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11418461'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">FR regimen: <b>IV:</b> 25 mg/m<sup>2</sup> once daily for 5 days during weeks 5, 9, 13, 19, 23, and 27 (in combination with rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19015393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19015393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">FCR regimen: <b>IV: </b>25 mg/m<sup>2</sup>/day on days 2 to 4 every 28 days (in combination with cyclophosphamide and rituximab) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21732338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21732338'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991202"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥80 mL/minute: No dosage adjustment necessary (administer the usual dose of 25 mg/m<sup>2</sup>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 50 to 79 mL/minute: Reduce dose to 20 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 49 mL/minute: Reduce dose to 15 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b> (Canadian product; not available in US):</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 70 mL/minute: Reduce dose by up to 50%.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have also been recommended: <b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Krens 2019:</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &gt;70 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR 30 to 70 mL/minute: Reduce dose to 80% of the original dose.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;30 mL/minute: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: Reduce dose to 80% of the original dose; start dialysis 12 hours after fludarabine administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Aronoff 2007:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 50 mL/minute: Reduce dose to 75% of usual dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: Reduce dose to 50% of usual dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CAPD: Reduce dose to 50% of usual dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CRRT: Reduce dose to 75% of usual dose.</p></div>
<div class="block doha drugH1Div" id="F50988388"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment for hepatic impairment is not likely necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F171840"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and may be derived from higher than approved dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (15%), nausea and vomiting (36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression (&gt;30%, including anemia, bone marrow aplasia [trilineage], neutropenia, pancytopenia, thrombocytopenia)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (33%, including herpes zoster infection [reactivation], opportunistic infection, reactivation of latent Epstein-Barr virus, upper respiratory tract infection [2%])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (11%), neurotoxicity (21%, including agitation, asthenia [9%], blindness, cerebral hemorrhage, coma, confusion, optic neuritis, optic neuropathy, peripheral neuropathy, seizure, visual disturbance [3%], wrist-drop), pain (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary toxicity (35%, including acute respiratory distress syndrome, pneumonia [16%], pneumonitis, pulmonary fibrosis, pulmonary hemorrhage, pulmonary hypersensitivity reaction, respiratory distress, respiratory failure)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (60%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Aneurysm (1%), deep vein thrombosis (1%), edema (8%), phlebitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (1%), pruritus (1%), seborrhea (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (1%), hyperglycemia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (7%), constipation (1%), dysphagia (1%), esophagitis (3%), gastrointestinal hemorrhage (3%), stomatitis (2% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (4%), hematuria (2%), proteinuria (1%), urinary tract infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (1%), tumor lysis syndrome (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (1%, including increased liver enzymes), hepatic failure (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebellar syndrome (1%), depression (1%), difficulty thinking (1%), fatigue (10%), headache (3%), malaise (8%), paresthesia (4%), sleep disturbance (1%), transient ischemic attacks (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1%), myalgia (4%), osteoporosis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Altered kidney function test (1%), kidney failure (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (1%), cough (10%), dyspnea (9%), epistaxis (1%), hemoptysis (1%), hypoxia (1%), sinusitis (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic &amp; oncologic: Myelofibrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrythmia, heart failure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, malignant neoplasm of skin (new onset or exacerbation), pemphigus, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Lactic acidosis (Smith 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Increased pancreatic enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hemorrhagic cystitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acquired blood coagulation disorder, acute myelocytic leukemia, autoimmune hemolytic anemia (Tsiara 1997), autoimmune thrombocytopenia (Sen 1999), Evan syndrome (Sen 1999), hemolysis (autoimmune) (Sen 1999), hemophagocytic lymphohistiocytosis (Jayakody Arachchillage 2014), immune thrombocytopenia, myelodysplastic syndrome (Yamazaki 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Epstein-Barr-associated lymphoproliferative disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: JC virus infection (reactivation: progressive multifocal leukoencephalopathy) (Vidarsson 2002), mycobacterium infection (including tuberculosis [extrapulmonary abscess]) (Leung 2005), reactivation of HBV (Yağci 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Vision loss (Virgo 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis (Garg 2002), pulmonary neoplasm (nodule) (Garg 2002)</p></div>
<div class="block coi drugH1Div" id="F171854"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Hypersensitivity to fludarabine or any component of the formulation; severe renal impairment (CrCl &lt;30 mL/minute); decompensated hemolytic anemia; concurrent use with pentostatin.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F171837"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune effects: Life-threatening (and sometimes fatal) autoimmune effects, including hemolytic anemia, autoimmune thrombocytopenia/thrombocytopenic purpura, Evans syndrome, and acquired hemophilia, have occurred. This has occurred in patients with and without a history of autoimmune hemolytic anemia or a positive Coombs test, and who may or may not be in remission from their disease. Following fludarabine discontinuation, hemolytic effects recurred in most patients when rechallenged with fludarabine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Severe bone marrow suppression (anemia, thrombocytopenia, and neutropenia) may occur; may be cumulative. The median time to nadir was 13 days (range: 3 to 25 days) for granulocytes and 16 days (range: 2 to 32 days) for platelets. Severe myelosuppression (trilineage bone marrow hypoplasia/aplasia) has been reported (rare) with a duration of significant cytopenias ranging from 2 months to 1 year. First-line combination therapy is associated with prolonged cytopenias, with anemia lasting up to 7 months, neutropenia up to 9 months, and thrombocytopenia up to 10 months; increased age is predictive for prolonged cytopenias (Gill 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Serious and sometimes fatal infections, including opportunistic infections and reactivations of latent viral infections such as VZV (herpes zoster) and Epstein-Barr virus have been reported with fludarabine. Use with caution in patients with documented infection, fever, immunodeficiency, or with a history of opportunistic infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Higher than recommended doses (up to 96 mg/m<sup>2</sup>/day for 5 to 7 days) are associated with severe neurologic toxicity (delayed blindness, coma, death); similar neurotoxicity (agitation, coma, confusion, seizure) has been reported (rare) with standard chronic lymphocytic leukemia (CLL) doses (25 mg/m<sup>2</sup>/day for 5 days). Symptoms of neurotoxicity due to high doses appeared from 21 to 60 days following the last fludarabine dose, although neurotoxicity has been reported as early as 7 days and up to 225 days. Although administration of up to 15 courses of treatment have been used, the possible neurotoxic effects of chronic administration are unknown. Fatigue, weakness, visual disturbances, confusion, and seizures may occur; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (usually fatal) due to JC virus has been reported; most cases were in patients who had received prior and/or other concurrent chemotherapy. Onset may be a few weeks or may be delayed up to 1 year.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transfusion-associated graft-versus-host disease: Graft-versus-host disease (GVHD) has been observed following transfusion of non-irradiated blood in patients treated with fludarabine; fatal outcome has been observed. Patients receiving fludarabine should only receive irradiated blood products due to the potential for transfusion-related GVHD.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: May cause tumor lysis syndrome; risk is increased in patients with large tumor burden prior to treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pentostatin: The use of fludarabine in combination with pentostatin is not recommended. When fludarabine has been used in combination with pentostatin for the treatment of refractory CLL, an unacceptably high incidence of fatal pulmonary toxicity has occurred.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Live vaccines: Avoid vaccination with live vaccines during and after fludarabine treatment.</p></div>
<div class="block foc drugH1Div" id="F171848"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as phosphate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as phosphate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (2 mL); 50 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as phosphate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F171833"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323155"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fludarabine Phosphate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $237.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Fludarabine Phosphate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $113.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866914"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as phosphate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as phosphate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea, 2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fludara: 10 mg</p></div>
<div class="block admp drugH1Div" id="F52612851"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Consult specific protocols; IV infusion rates may vary by pediatric protocol.</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent IV infusion: Infuse over 30 minutes; a shorter infusion has been used in some protocols (Avramis 1998)</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous IV infusion with loading dose (bolus):</p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: Administer over 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9516951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9516951'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer at a constant rate of 10 mL/hour</p></div>
<div class="block adm drugH1Div" id="F171851"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> The manufacturer recommends administering over ~30 minutes (for the treatment of CLL). Continuous infusions and IV bolus over 15 minutes have been used for some off-label protocols (refer to individual studies for infusion rate details).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Tablet [Canadian product] may be administered with or without food; should be swallowed whole with water; do not chew, break, or crush.</p></div>
<div class="block hazard drugH1Div" id="F49132595"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F171862"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Store intact vials under refrigeration or at room temperature, as specified according to each manufacturer's labeling. Protect from light. Reconstituted solution or vials of the solution for injection that have been punctured (in use) should be used within 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet [Canadian product]: Store at 15°C to 30°C (59°F to 86°F); should be kept within packaging until use.</p></div>
<div class="block usep drugH1Div" id="F53566955"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of B-cell chronic lymphocytic leukemia (CLL) unresponsive to previous therapy with an alkylating agent-containing regimen (FDA approved in ages ≥18 years); has also been used in the treatment of relapsed acute lymphocytic leukemia (ALL) or acute myeloid leukemia (AML), reduced-intensity conditioning regimens prior to allogeneic hematopoietic stem cell transplantation, non-Hodgkin lymphomas (NHL), and AML in either refractory or in poor risk patients</p></div>
<div class="block mst drugH1Div" id="F171916"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fludarabine may be confused with cladribine, floxuridine, flucytosine, Flumadine</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fludara may be confused with FUDR</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299343"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F171842"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentostatin: May enhance the adverse/toxic effect of Fludarabine. Specifically, the risk of fatal pulmonary toxicity may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49306595"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should use effective contraception during therapy and for at least 6 months after the last fludarabine dose.</p>
<p style="text-indent:0em;margin-top:2em;">Fludarabine may damage testicular tissue and spermatozoa. Patients with partners who could become pregnant should use contraception during therapy and for at least 6 months after the last fludarabine dose (duration of effect is uncertain).</p></div>
<div class="block pri drugH1Div" id="F171856"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action, fludarabine may cause fetal harm if administered during pregnancy.</p></div>
<div class="block mopp drugH1Div" id="F53566938"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential, platelet count, hemoglobin, AST, ALT, creatinine, serum electrolytes, albumin, uric acid, and examination for visual changes; monitor for signs of infection and neurotoxicity</p></div>
<div class="block pha drugH1Div" id="F171836"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fludarabine inhibits DNA synthesis by inhibition of DNA polymerase and ribonucleotide reductase; also inhibits DNA primase and DNA ligase I</p></div>
<div class="block phk drugH1Div" id="F171853"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>: 11 to 96 L/m<sup>2</sup> (Johnson 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 2-fluoro-ara-A: ~19% to 29%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: IV: Fludarabine phosphate is rapidly dephosphorylated in the plasma to 2-fluoro-ara-A (active metabolite), which subsequently enters tumor cells and is phosphorylated by deoxycytidine kinase to the active triphosphate derivative (2-fluoro-ara-ATP)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 2-fluoro-ara-A: 50% to 65%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2-fluoro-ara-A: Adults: ~20 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Oral: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily) (Johnson 2000)</p></div>
<div class="block phksp drugH1Div" id="F51192582"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Total body clearance of the principal metabolite (2-fluoro-ara-A) correlates with CrCl. Mean body clearance is 124 mL/minute for patients with moderate renal impairment and 71 mL/minute for patients with severe renal impairment. In 2 patients with a median CrCl of 22 mL/minute/m<sup>2</sup>, clearance was reduced by 56%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F171857"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Agule | Fludakebir | Fludara | Fludarabina filaxis | Fludarabina ima | Fludarabina Tuteur | Fludarabina varifarma</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabin accord | Fludarabinphosphat Actavis | Fludarabinphosphat Hospira | Fludarabinphosphat Pharmachemie | Neoflubin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Farine | Fludara | Fludarabine | Fludarabine actavis | Fludarabine an | Fludarabine ebewe | Fludarabine juno</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine accord healthcare | Fludarabine ebewe | Fludarabine fresenius kabi</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine accord | Fludarabine actavis</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Evoflubina | Fludalibbs | Fludara</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabin accord | Fludarabin ebewe | Fludarabin Labatec | Fludarabin sandoz</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabina fosfato</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fu da long | Rui zhi wan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aldarabina | Fludara | Fludarabina | Forclina | Ludabina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabin actavis | Fludarabine accord | Fludarabine Teva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bendarabin | Beneflur | Fludara | Fludarabin | Fludarabin accord | Fludarabin actavis | Fludarabin aurobindo | Fludarabin Omnicar | Fludarabinphosphat Hospira | Fludarabinphosphat omnicare</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabina | Fludarabina fosfato | Fludarabina kemex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine actavis | Fludarabine ebewe | Fludarabine Teva</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Beneflur | Fludarabina Accord | Fludarabina actavis | Fludarabina Ebewe | Fosfato de fludarabina Hospira</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabin actavis | Fludarabin ebewe | Fludarabine accord</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine accord | Fludarabine actavis | Fludarabine ebewe | Fludarabine Mylan | Fludarabine phosphate hospira | Fludarabine Teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine | Trav fludarabine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabin/ebewe | Fludarabine/specifar</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Fludalym | Fludara | Fludarabin ebewe</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabin | Fludarabin accord</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Fludabine | Fludacel | Fludara | Fludocyte</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabina | Fludarabina Accord | Fludarabina Act | Fludarabina Ebe | Fludarabina Mylan</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine | Pfizer fludarabin | Samoh fludarabine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fludacel | Fludara | Fludarabin actavis | Fludarabine | Fludarabine accord | Fludarabine actavis | Fludarabine Teva</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Asoleudox | Fludara</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine kabi</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine | Fludarabine sandoz | Fludarabinefosfaat Actavis</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabin | Fludarabin ebewe | Fludarabine Pharmachemie</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Mepredin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Neoflubin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Fludalym | Fludara | Fludarabin ebewe | Fludarabine accord | Fludarabine actavis | Fludarabine Teva</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabina | Fludarabina Accord | Fludarabina Teva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Darabin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabina actavis</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Darbines | Fludara | Fludarabin | Fludarabin actavis | Fludarabin ebewe | Fludarabin teva | Flugarda | Vero fludarabin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabin actavis | Fludarabin ebewe | Fludarabin hospira | Fludarabine accord</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabin teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabin ebewe</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Fludarabine ebewe</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Darabin | Fludalym | Fludara | Flumen</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fludara</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Fludabin | Fludabine | Fludameda | Fludara | Fludarabin | Fludarabine</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Darabin | Fludarabina fu</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Fludara | Teva Fludarabine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32888407">
<a name="32888407"></a>Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. <i>Lancet</i>. 2020;396(10254):839-852. doi:10.1016/S0140-6736(20)31366-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/32888407/pubmed" id="32888407" target="_blank">32888407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15806128">
<a name="15806128"></a>Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. <i>Bone Marrow Transplant</i>. 2005;35(10):943-951. doi:10.1038/sj.bmt.1704942<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/15806128/pubmed" id="15806128" target="_blank">15806128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007, p 99, 172.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9516951">
<a name="9516951"></a>Avramis VI, Wiersma S, Krailo MD, et al. Pharmacokinetic and Pharmacodynamic Studies of Fludarabine and Cytosine Arabinoside Administered as Loading Boluses Followed by Continuous Infusions After a Phase I/II Study in Pediatric Patients With Relapsed Leukemias. The Children's Cancer Group. <i>Clin Cancer Res</i>. 1998;4(1):45-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/9516951/pubmed" id="9516951" target="_blank">9516951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25652604">
<a name="25652604"></a>Baron F, Zachée P, Maertens J, et al. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. <i>J Hematol Oncol.</i> 2015;8:4. doi:10.1186/s13045-014-0098-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/25652604/pubmed" id="25652604" target="_blank">25652604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34175021">
<a name="34175021"></a>Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet</i>. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/34175021/pubmed" id="34175021" target="_blank">34175021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24797180">
<a name="24797180"></a>Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. <i>Bone Marrow Transplant</i>. 2014;49(7):913-920.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/24797180/pubmed" id="24797180" target="_blank">24797180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24990142">
<a name="24990142"></a>Borthakur G, Cortes JE, Estey EE, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. <i>Am J Hematol.</i> 2014;89(10):964-968. doi:10.1002/ajh.23795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/24990142/pubmed" id="24990142" target="_blank">24990142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18932257">
<a name="18932257"></a>Borthakur G, Kantarjian H, Wang X, et al. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. <i>Cancer</i>. 2008;113(11):3181-3185. doi:10.1002/cncr.23927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/18932257/pubmed" id="18932257" target="_blank">18932257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24462742">
<a name="24462742"></a>Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/24462742/pubmed" id="24462742" target="_blank">24462742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23940227">
<a name="23940227"></a>Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. <i>J Clin Oncol</i>. 2013;31(27):3360-3368. doi:10.1200/JCO.2012.47.4874<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/23940227/pubmed" id="23940227" target="_blank">23940227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12393429">
<a name="12393429"></a>Byrd JC, Peterson BL, Morrison VA, et al. Randomized Phase 2 Study of Fludarabine With Concurrent vs Sequential Treatment With Rituximab in Symptomatic, Untreated Patients With B-Cell Chronic Lymphocytic Leukemia: Results From Cancer and Leukemia Group B 9712 (CALGB 9712). <i>Blood</i>. 2003;101(1):6-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/12393429/pubmed" id="12393429" target="_blank">12393429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33091356">
<a name="33091356"></a>Castillo JJ, Advani RH, Branagan AR, et al. Kastritis E. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematol.</i> 2020;7(11):e827-e837. doi:10.1016/S2352-3026(20)30224-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/33091356/pubmed" id="33091356" target="_blank">33091356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11756155">
<a name="11756155"></a>Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. <i>Blood.</i> 2002;99(1):75-82. doi:10.1182/blood.v99.1.75<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/11756155/pubmed" id="11756155" target="_blank">11756155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22892917">
<a name="22892917"></a>Costa RO, Bellesso M, Chamone DA, et al. T-cell large granular lymphocytic leukemia: treatment experience with fludarabine. <i>Clinics (Sao Paulo)</i>. 2012;67(7):745-748. doi:10.6061/clinics/2012(07)07<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/22892917/pubmed" id="22892917" target="_blank">22892917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11418461">
<a name="11418461"></a>Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). <i>Blood</i>. 2001;98(1):41-48. doi:10.1182/blood.v98.1.41<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/11418461/pubmed" id="11418461" target="_blank">11418461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216274">
<a name="27216274"></a>Eichhorst B, Fink AM, Bahlo J, et al; International Group of Investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.<i> Lancet Oncol.</i> 2016;17(7):928-942. doi:10.1016/S1470-2045(16)30051-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/27216274/pubmed" id="27216274" target="_blank">27216274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16219797">
<a name="16219797"></a>Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine Plus Cyclophosphamide Versus Fludarabine Alone in First-Line Therapy of Younger Patients With Chronic Lymphocytic Leukemia. <i>Blood</i>. 2006;107(3):885-891.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/16219797/pubmed" id="16219797" target="_blank">16219797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26486789">
<a name="26486789"></a>Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. <i>Blood</i>. 2016;127(2):208-215. doi:10.1182/blood-2015-06-651125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/26486789/pubmed" id="26486789" target="_blank">26486789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17283364">
<a name="17283364"></a>Flinn IW, Neuberg DS, Grever MR, et al. Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997. <i>J Clin Oncol</i>. 2007;25(7):793-798.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/17283364/pubmed" id="17283364" target="_blank">17283364</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Fludara (fludarabine phosphate tablet) [product monograph]. Lavel, Quebec, Canada: Sanofi Aventis Canada Inc; September 2014.</div>
</li>
<li>
<div class="reference">
                  Fludarabine phosphate injection [prescribing information]. Georgetown, IN: Areva Pharmaceuticals; October 2018.</div>
</li>
<li>
<div class="reference">
                  Fludarabine phosphate injection [prescribing information]. Georgetown, IN: Areva Pharmaceuticals; January 2019.</div>
</li>
<li>
<div class="reference">
                  Fludarabine phosphate injection [prescribing information]. Lake Forest, IL: Hospira Inc; May 2018.</div>
</li>
<li>
<div class="reference">
                  Fludarabine phosphate injection [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA; October 2015.</div>
</li>
<li>
<div class="reference">
                  Fludarabine phosphate injection [prescribing information]. Schaumberg, IL: Sagent Pharmaceuticals; August 2016.</div>
</li>
<li>
<div class="reference">
                  Fludarabine phosphate injection [product monograph]. Saint Laurent, Quebec, Canada: Hospira Healthcare Corporation; February 2015.</div>
</li>
<li>
<div class="reference">
                  Fludarabine phosphate injection, USP [product monograph]. Kirkland, Quebec, Canada: Accord Healthcare Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10080598">
<a name="10080598"></a>Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. <i>J Clin Oncol</i>. 1999;17(2):546-553. doi:10.1200/JCO.1999.17.2.546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/10080598/pubmed" id="10080598" target="_blank">10080598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12111771">
<a name="12111771"></a>Garg S, Garg MS, Basmaji N. Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature. <i>Am J Hematol</i>. 2002;70(3):241-245. doi:10.1002/ajh.10144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/12111771/pubmed" id="12111771" target="_blank">12111771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19625344">
<a name="19625344"></a>Gill S, Carney D, Ritchie D, et al. The Frequency, Manifestations, and Duration of Prolonged Cytopenias After First-Line Fludarabine Combination Therapy. <i>Ann Oncol</i>. 2010;21(2):331-334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/19625344/pubmed" id="19625344" target="_blank">19625344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16344316">
<a name="16344316"></a>Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. <i>J Clin Oncol</i>. 2006;24(3):444-453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/16344316/pubmed" id="16344316" target="_blank">16344316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512246">
<a name="23512246"></a>Hopfinger G, Busch R, Pflug N, et al. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. <i>Cancer</i>. 2013;119(12):2258-2267. doi:10.1002/cncr.27972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/23512246/pubmed" id="23512246" target="_blank">23512246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jacobson.1">
<a name="Jacobson.1"></a>Jacobson C, Chavez JC, Sehgal AR, et al. Primary analysis of zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-hodgkin lymphoma (iNHL) [abstract 623 from ASH 2020 annual meeting]. <i>Blood.</i> 2020;136(suppl 1):40-41. doi:10.1182/blood-2020-136834</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24628491">
<a name="24628491"></a>Jayakody Arachchillage D, Hurst E, Carey P, et al. Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia. <i>Br J Haematol</i>. 2014;166(1):142-145. doi:10.1111/bjh.12822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/24628491/pubmed" id="24628491" target="_blank">24628491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10926348">
<a name="10926348"></a>Johnson SA. Clinical Pharmacokinetics of Nucleoside Analogues: Focus on Haematological Malignancies. <i>Clin Pharmacokinet</i>. 2000;39(1):5-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/10926348/pubmed" id="10926348" target="_blank">10926348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15767648">
<a name="15767648"></a>Keating MJ, O'Brien S, Albitar M, et al. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia. <i>J Clin Oncol</i>. 2005;23(18):4079-4088.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/15767648/pubmed" id="15767648" target="_blank">15767648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18411419">
<a name="18411419"></a>Khouri IF, McLaughlin P, Saliba RM, et al. Eight-Year Experience With Allogeneic Stem Cell Transplantation for Relapsed Follicular Lymphoma After Nonmyeloablative Conditioning With Fludarabine, Cyclophosphamide, and Rituximab. <i>Blood</i>. 2008;111(12):5530-5536.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/18411419/pubmed" id="18411419" target="_blank">18411419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190991">
<a name="21190991"></a>Lamy T, Loughran TP Jr. How I treat LGL leukemia. <i>Blood</i>. 2011;117(10):2764-2774. doi:10.1182/blood-2010-07-296962<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/21190991/pubmed" id="21190991" target="_blank">21190991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18000167">
<a name="18000167"></a>Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for Untreated Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>Blood</i>. 2008;111(3):1044-1053.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/18000167/pubmed" id="18000167" target="_blank">18000167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15981223">
<a name="15981223"></a>Leung WH, Tsang SF, Chim CS. Extrapulmonary tuberculous abscess in chronic lymphocytic leukaemia (CLL) treated with fludarabine: case report and review of literature. <i>Am J Hematol</i>. 2005;79(3):246-247. doi:10.1002/ajh.20322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/15981223/pubmed" id="15981223" target="_blank">15981223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30518502">
<a name="30518502"></a>Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. <i>Lancet Oncol</i>. 2019;20(1):31-42. doi:10.1016/S1470-2045(18)30864-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/30518502/pubmed" id="30518502" target="_blank">30518502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34891224">
<a name="34891224"></a>Locke FL, Miklos DB, Jacobson CA, et al; All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. <i>N Engl J Med.</i> 2022;386(7):640-654. doi:10.1056/NEJMoa2116133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/34891224/pubmed" id="34891224" target="_blank">34891224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29385370">
<a name="29385370"></a>Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. <i>N Engl J Med</i>. 2018;378(5):439-448. doi:10.1056/NEJMoa1709866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/29385370/pubmed" id="29385370" target="_blank">29385370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9625576">
<a name="9625576"></a>Montillo M, Mirto S, Petti MC, et al. Fludarabine, Cytarabine, and G-CSF (FLAG) for the Treatment of Poor Risk Acute Myeloid Leukemia. <i>Am J Hematol</i>. 1998;58(2):105-109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/9625576/pubmed" id="9625576" target="_blank">9625576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33626253">
<a name="33626253"></a>Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. <i>N Engl J Med</i>. 2021;384(8):705-716. doi:10.1056/NEJMoa2024850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/33626253/pubmed" id="33626253" target="_blank">33626253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29226797">
<a name="29226797"></a>Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. <i>N Engl J Med</i>. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/29226797/pubmed" id="29226797" target="_blank">29226797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12393457">
<a name="12393457"></a>Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. <i>Blood</i>. 2003;101(4):1620-1629. doi:10.1182/blood-2002-05-1340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/12393457/pubmed" id="12393457" target="_blank">12393457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21131038">
<a name="21131038"></a>Parker C, Waters R, Leighton C, et al. Effect of Mitoxantrone on Outcome of Children With First Relapse of Acute Lymphoblastic Leukaemia (ALL R3): An Open-Label Randomised Trial. <i>Lancet</i>. 2010;376(9757):2009-2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/21131038/pubmed" id="21131038" target="_blank">21131038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35020191">
<a name="35020191"></a>Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenström macroglobulinaemia-a British Society for Haematology guideline.<i> Br J Haematol</i>. 2022;197(2):171-187. doi:10.1111/bjh.18036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/35020191/pubmed" id="35020191" target="_blank">35020191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19528536">
<a name="19528536"></a>Pulsipher MA, Boucher KM, Wall D, et al. Reduced-Intensity Allogeneic Transplantation in Pediatric Patients Ineligible for Myeloablative Therapy: Results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. <i>Blood</i>. 2009;114(7):1429-1436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/19528536/pubmed" id="19528536" target="_blank">19528536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26429297">
<a name="26429297"></a>Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncol</i>. 2015;16(15):1525-1536.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/26429297/pubmed" id="26429297" target="_blank">26429297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056679">
<a name="18056679"></a>Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma. <i>J Clin Oncol</i>. 2008;26(2):211-217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/18056679/pubmed" id="18056679" target="_blank">18056679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20194844">
<a name="20194844"></a>Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia. <i>J Clin Oncol</i>. 2010;28(10):1756-1765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/20194844/pubmed" id="20194844" target="_blank">20194844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14716342">
<a name="14716342"></a>Schetelig J, Bornhauser M, Kiehl M, et al. Reduced-Intensity Conditioning With Busulfan and Fludarabine With or Without Antithymocyte Globulin in HLA-Identical Sibling Transplantation - A Retrospective Analysis. <i>Bone Marrow Transplant</i>. 2004;33(5):483-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/14716342/pubmed" id="14716342" target="_blank">14716342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501490">
<a name="30501490"></a>Schuster SJ, Bishop MR, Tam CS, et al; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. <i>N Engl J Med</i>. 2019;380(1):45-56. doi:10.1056/NEJMoa1804980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/30501490/pubmed" id="30501490" target="_blank">30501490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10398320">
<a name="10398320"></a>Sen K, Kalaycio M. Evan's syndrome precipitated by fludarabine therapy in a case of CLL. <i>Am J Hematol</i>. 1999;61(3):219. doi:10.1002/(sici)1096-8652(199907)61:3&lt;219::aid-ajh15&gt;3.0.co;2-#<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/10398320/pubmed" id="10398320" target="_blank">10398320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34097852">
<a name="34097852"></a>Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. <i>Lancet</i>. 2021;398(10299):491-502. doi:10.1016/S0140-6736(21)01222-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/34097852/pubmed" id="34097852" target="_blank">34097852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31361914">
<a name="31361914"></a>Smith ZR, Horng M, Rech MA. Medication-induced hyperlactatemia and lactic acidosis: a systematic review of the literature. <i>Pharmacotherapy</i>. 2019;39(9):946-963.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/31361914/pubmed" id="31361914" target="_blank">31361914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31247313">
<a name="31247313"></a>Solomon SR, Solh M, Zhang X, et al. Fludarabine and total-body irradiation conditioning before ablative haploidentical transplantation: long-term safety and efficacy. <i>Biol Blood Marrow Transplant.</i> 2019;25(11):2211-2216. doi:10.1016/j.bbmt.2019.06.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/31247313/pubmed" id="31247313" target="_blank">31247313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12588360">
<a name="12588360"></a>Sternberg A, Eagleton H, Pillai N, et al. Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity. <i>Br J Haematol</i>. 2003;120(4):699-701. doi:10.1046/j.1365-2141.2003.04148.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/12588360/pubmed" id="12588360" target="_blank">12588360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16314618">
<a name="16314618"></a>Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. <i>J Clin Oncol</i>. 2005;23(36):9387-9393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/16314618/pubmed" id="16314618" target="_blank">16314618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21732338">
<a name="21732338"></a>Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. <i>Cancer</i>. 2012;118(2):434-443. doi:10.1002/cncr.26303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/21732338/pubmed" id="21732338" target="_blank">21732338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19015393">
<a name="19015393"></a>Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. <i>Blood</i>. 2009;113(16):3673-3678. doi:10.1182/blood-2008-09-177329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/19015393/pubmed" id="19015393" target="_blank">19015393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10398320">
<a name="10398320"></a>Tsiara S, Christou L, Konstantinidou P, Panteli A, Briasoulis E, Bourantas KL. Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia. <i>Am J Hematol</i>. 1997;54(4):342.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/10398320/pubmed" id="10398320" target="_blank">10398320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12393618">
<a name="12393618"></a>Tsimberidou AM, McLaughlin P, Younes A, et al. Fludarabine, Mitoxantrone, Dexamethasone (FND) Compared With an Alternating Triple Therapy (ATT) Regimen in Patients With Stage IV Indolent Lymphoma. <i>Blood</i>. 2002;100(13):4351-4357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/12393618/pubmed" id="12393618" target="_blank">12393618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18182662">
<a name="18182662"></a>Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. <i>J Clin Oncol</i>. 2008;26(2):196-203. doi:10.1200/JCO.2007.11.8513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/18182662/pubmed" id="18182662" target="_blank">18182662</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11994982">
<a name="11994982"></a>Vidarsson B, Mosher DF, Salamat MS, Isaksson HJ, Onundarson PT. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. <i>Am J Hematol</i>. 2002;70(1):51-54. doi:10.1002/ajh.10085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/11994982/pubmed" id="11994982" target="_blank">11994982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14675405">
<a name="14675405"></a>Virchis A, Koh M, Rankin P, et al. Fludarabine, Cytosine Arabinoside, Granulocyte-Colony Stimulating Factor With or Without Idarubicin in the Treatment of High Risk Acute Leukaemia of Myelodysplastic Syndromes. <i>Br J Haematol</i>. 2004;124(1):26-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/14675405/pubmed" id="14675405" target="_blank">14675405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30692648">
<a name="30692648"></a>Virgo J, Williams G, Stanford M. Visual loss secondary to fludarabine toxicity: optical coherence tomography findings in two patients. <i>Eye (Lond)</i>. 2019;33(6):1023-1025. doi:10.1038/s41433-019-0343-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/30692648/pubmed" id="30692648" target="_blank">30692648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10861827">
<a name="10861827"></a>Yağci M, Sucak GT, Haznedar R. Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia. <i>Am J Hematol</i>. 2000;64(3):233-234. doi:10.1002/1096-8652(200007)64:3&lt;233::aid-ajh21&gt;3.0.co;2-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/10861827/pubmed" id="10861827" target="_blank">10861827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23257533">
<a name="23257533"></a>Yamazaki S, Nakamura F, Nannya Y, Nakagawa M, Ichikawa M, Kurokawa M. Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy. <i>Intern Med</i>. 2012;51(24):3427-3430. doi:10.2169/internalmedicine.51.8310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/23257533/pubmed" id="23257533" target="_blank">23257533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32242358">
<a name="32242358"></a>Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. <i>N Engl J Med</i>. 2020;382(14):1331-1342. doi:10.1056/NEJMoa1914347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/32242358/pubmed" id="32242358" target="_blank">32242358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15767647">
<a name="15767647"></a>Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>J Clin Oncol</i>. 2005;23(18):4070-4078.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludarabine-pediatric-drug-information/abstract-text/15767647/pubmed" id="15767647" target="_blank">15767647</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13305 Version 320.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
